English 日本語

#TakedaPharmaceuticalCompanyLimited

List of IR information related to "TakedaPharmaceuticalCompanyLimited".

2 IR Posts
1 Companies
29 days ago Last Updated

Filters

Reset
Period:
Importance:
2 IR Posts
4502 Takeda Pharmaceutical Company Limited
2025/12/18
Innovative Phase 3 Clinical Trial Data Demonstrates Zasositinib, Administered Once Daily Orally for Plaque Psoriasis, Improves Skin Lesions and Opens a New Era in Treatment

Zasositinib (TAK-279) achieved primary endpoints in a Phase 3 clinical trial targeting patients with moderate to severe plaque psoriasis, with over half achieving PASI90 and approximately 30% achieving PASI100 at week 16.

Strategy/Investment,Other
#TakedaPharmaceuticalCompanyLimited #Zasositinib #NewProduct
4502 Takeda Pharmaceutical Company Limited
2025/12/08
Announcement of Long-term rusfertide Data Demonstrating Sustained Hematocrit Control in Polycythemia Vera at the 67th Annual Meeting of the American Society of Hematology (ASH) in Collaboration with Protagonist Therapeutics

Takeda Pharmaceutical Company Limited, in collaboration with Protagonist Therapeutics, announced 52-week data from the Phase 3 VERIFY trial of rusfertide in patients with polycythemia vera, demonstrating sustained hematocrit control and safety.

Strategy/Investment,Other
#TakedaPharmaceuticalCompanyLimited #rusfertide #NewProduct
Scroll to Top